Orthocell expands into HK with Ortho-ATI
Regenerative medicine company Orthocell (ASX:OCC) has expanded the reach for its Ortho-ATI tendon repair therapy, recording its first sales in Hong Kong.
The first two Hong Kong patients have been treated with the stem cell-based therapy by orthopaedic surgeon Jason Brockwell from sports orthopaedic group Asia Medical Specialists.
Ortho-ATI involves taking tendon cells from a patient, culturing them and injecting them into the patient’s damaged tendon to help regenerate the damaged tissue.
Orthocell is targeting expansion into Asia as a key strategy for the product, and managing director Paul Anderson called the Hong Kong win “an important step forward” for these efforts.
“There is great interest for a clinically effective treatment that has long-term durability and cost-effectiveness,” he said.
APAC is expected to be the fastest-growing region for the global regenerative medicine market through to 2020, according to Allied Market Research. The global market is on track to grow to US$67.6 billion ($87 billion) by this time, up from US$16.4 billion in 2013.
Orthocell also recently picked up a Chinese patent covering its Celgro collagen reconstructive platform technology as part of its Asian expansion plans.
Orthocell (ASX:OCC) shares were trading 2.6% higher at $0.39 as of around 1.30 pm on Monday.
More effective antibiotic found for Lyme disease
Researchers have found that piperacillin, an antibiotic in the same class as penicillin,...
Why do our waistlines expand in middle age?
A new preclinical study highlights the importance of controlling new fat-cell formation to...
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
